Lignes directrices de pratique clinique 2008 de l - Canadian ...

S34 | LiGneS DireCTriCeS De PraTiqUe CLiniqUe 2008
New Engl J Med. 2008;358:2545-2559.
6. The ADVANCE Collaborative Group. Intensive blood glucose
control and vascular outcomes in patients with type 2 diabetes.
New Engl J Med. 2008;358:2560-2572.
7. The Diabetes Control and Complications Trial Research Group.
The relationship of glycemic exposure (HbA1c) to the risk of
development and progression of retinopathy in the Diabetes
Control and Complications Trial. Diabetes. 1995;44:968-983.
8. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia
with macrovascular and microvascular complications of type 2
diabetes (UKPDS 35): prospective observational study. BMJ.
2000;321:405-412.
9. Standl E, Balletshofer B, Dahl B, et al. Predictors of 10-year
macrovascular and overall mortality in patients with NIDDM:
the Munich General Practitioner Project. Diabetologia. 1996;39:
1540-1545.
10. Service FJ, O’Brien PC. The relation of glycaemia to the risk
of development and progression of retinopathy in the Diabetic
[sic] Control and Complications Trial. Diabetologia. 2001;44:
1215-1220.
11. Coutinho M, Gerstein HC, Wang Y, et al. The relationship
between glucose and incident cardiovascular events. A metaregression
analysis of published data from 20 studies of 95,783
individuals followed for 12.4 years. Diabetes Care. 1999;22:
233-240.
12. Levitan EB, Song Y, Ford ES, et al. Is nondiabetic hyperglycemia
a risk factor for cardiovascular disease? Arch Intern Med.
2004;164:2147-2155.
13. DECODE Study Group, European Diabetes Epidemiology
Group. Is current definition for diabetes relevant to mortality
risk from all causes and cardiovascular and noncardiovascular
causes? Diabetes Care. 2003;26:688-696.
14. Sorkin JD, Muller DC, Fleg JL, et al. The relation of fasting and
2-h postchallenge plasma glucose to mortality: data from the
Baltimore Longitudinal Study of Aging with a critical review of
the literature. Diabetes Care. 2005;28:2626-2632.
15. Chaisson JL, Josse RG, Gomis R, et al. Acarbose treatment and
the risk of cardiovascular disease and hypertension in patients
with impaired glucose tolerance: the STOP-NIDDM Trial.
JAMA. 2003;290:486-494.
16. Shiraiwa T, Kaneto H, Miyatsuka T, et al. Post prandial hyperglycemia
is an important predictor of the incidence of diabetic
microangiopathy in Japanese type 2 diabetic patients. Biochem
Biophys Res Commun. 2005;336:339-345.
17. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial
infarction and death in newly detected NIDDM: the
Diabetes Intervention Study, 11-year follow-up. Diabetologia.
1996;39:1577-1583.
18. Monnier L, Lapinski H, Colette C. Contributions of fasting and
postprandial plasma glucose increments to the overall diurnal
hyperglycemia of type 2 diabetic patients. Diabetes Care.
2003;26:881-885.
19. Woerle HHJ, Neumann C, Zschau S, et al. Impact of fasting
and postprandial glycemia on overall glycemic control in type 2
diabetes. Importance of postprandial glycemia to achieve target
HbA1c levels. Diab Res Clin Pract. 2007;77:280-285.
20. Monnier L, Colette C, Dunseath GJ, et al. The loss of postprandial
glycemic control precedes stepwise deterioration of fasting
with worsening diabetes. Diabetes Care. 2007;30:263-269.